



## Predicting Serious Drug Side Effects in Gastroenterology - PRED4

### International IBD Genetics Consortium Projects

[www.ibdresearch.co.uk/pred4](http://www.ibdresearch.co.uk/pred4)


**Welcome to the 4<sup>th</sup> edition newsletter of 2014.** 38 sites have recruited patients to PRED4 since the last newsletter. We also have 4 new recruiters: Birmingham Childrens, Lincoln, Maidstone and Manchester Royal. Thank you and well done.

•**Targets:** We are happy for you to recruit over your targets set in the SSI form so if you have reached your target please don't let that hold you back.

•**Twitter:** You can follow up to date news on the PRED4 study at **@PRED4research**.



**We have submitted the amendment 5 to the Research Ethics Committee and this has been uploaded on to CSP for R&D review. This amendment is to extend recruitment of all six arms of the study until December 2015 and to add a new arm to the study - Thiopurine Hypersensitivity Reaction. We have attached the CRF's for all the study arms to this newsletter. Also we would like to draw your attention to 2 patient adverts, that we hope will assist in patient identification. These have also been attached to this newsletter.**



#### **Inclusion and Exclusion criteria for the new arm: Thiopurine Hypersensitivity Reaction (THR)**

##### Inclusion Criteria

- Aged 6 years or over
- History of Inflammatory Bowel Disease
- History of thiopurine exposure in the previous 7 days before the onset of adverse event.
- Flu like symptoms severe enough to lead to drug withdrawal even if temporary (symptoms should include fever, muscle ache, joint pain)
- Onset of symptoms within 4 weeks of starting thiopurine.
- Symptoms resolved within 14 days of drug withdrawal.

##### Exclusion Criteria

- Patient tolerated re-challenge with the same thiopurine regardless of dose.
- Drug withdrawn due to nausea and/or diarrhoea without any other symptoms
- Objective evidence of Infection at the time of the hypersensitivity reaction.

#### **Reminder of the Inclusion Criteria for Thiopurine Induced Liver Injury (TIH)**

- History of inflammatory bowel disease
- Normal ALT and bilirubin at baseline
- No pre-existing liver disease
- Elevation of ALT and/or bilirubin to  $\geq 5$  times upper limit of normal (guidance  $>175$  for female and  $>200$  for males.)
- History of thiopurine exposure in the previous 30 days prior to this abnormal blood test
- Medical opinion implicating thiopurine in development of hepatotoxicity

#### **CHRISTMAS CLOSURE**

**The Pharmacogenetics Office will be closed 24th December 2014 - 5th January 2015. You can still send in samples to the lab as the lab staff will be working over this period.**

**If you have any urgent queries you may call our Research Nurse Suzie Marriott on 01392 408937 or 07810 834996 who will be available on 24th, 30th and 31st December and the 2nd January.**

**The electronic CRFs are designed to replace the paper CRFs and can be completed on the database [www.ibdresearch.net](http://www.ibdresearch.net) - please contact us for your username and password.**

**As always if you have any feedback or suggestions on how to improve the study please let us know . If you have found a good way to find patients why not post it on Twitter.**

Marian Parkinson  
Tel: 01392 406851  
[marian.parkinson@nhs.net](mailto:marian.parkinson@nhs.net)

Dr Tariq Ahmad (Chief Investigator)  
E-mail: [tariq.ahmad1@nhs.net](mailto:tariq.ahmad1@nhs.net)

Claire Bewshea –  
IBD Research Project Manager  
E-mail: [claire.bewshea@nhs.net](mailto:claire.bewshea@nhs.net)  
Tel: 01392 406850  
Mobile: 07828146468

**Junior doctors:**  
Dr Abhey Singh (TNF/TIM)  
[abhey.singh@nhs.net](mailto:abhey.singh@nhs.net)

Dr Graham Heap (TIP)  
[grahamheap@nhs.net](mailto:grahamheap@nhs.net)

Dr Naomi Edney (PPI)  
[naomi.edney@nhs.net](mailto:naomi.edney@nhs.net)

**We have two new programme administrators Helen Gardner-Thorpe and Hanlie Olivier**  
[h.gardner-thorpe@nhs.net](mailto:h.gardner-thorpe@nhs.net)  
Tel: 01392 406852

